Personalis Receivables 2018-2024 | PSNL

Personalis receivables from 2018 to 2024. Receivables can be defined as the total amount of collectibles for a company
Personalis Annual Receivables
(Millions of US $)
2023 $18
2022 $17
2021 $18
2020 $6
2019 $3
2018 $4
2017 $
Personalis Quarterly Receivables
(Millions of US $)
2024-09-30 $13
2024-06-30 $13
2024-03-31 $11
2023-12-31 $18
2023-09-30 $14
2023-06-30 $10
2023-03-31 $18
2022-12-31 $17
2022-09-30 $14
2022-06-30 $13
2022-03-31 $14
2021-12-31 $18
2021-09-30 $11
2021-06-30 $9
2021-03-31 $8
2020-12-31 $6
2020-09-30 $6
2020-06-30 $5
2020-03-31 $6
2019-12-31 $3
2019-09-30 $4
2019-06-30 $7
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.239B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.350B 6.35
Dr Reddy's Laboratories (RDY) India $11.677B 22.35
BridgeBio Pharma (BBIO) United States $4.392B 0.00
Bausch Health Cos (BHC) Canada $3.009B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.142B 12.88
Supernus Pharmaceuticals (SUPN) United States $1.978B 26.93
Taysha Gene Therapies (TSHA) United States $0.447B 31.14
Assembly Biosciences (ASMB) United States $0.094B 0.00
Sol-Gel Technologies (SLGL) Israel $0.013B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00